MCL1 and melanoma: For example, MCL-1 inhibitors (e.g., S63845 or AMG 176) have been combined with inhibitors against MEK, HER-2, B-RAF or EGFR and shown to induce a cytotoxic response in solid tumours such as breast, non-small cell lung cancer, lung adenocarcinoma and melanoma cells [243,253].